The ABHD14B Knockout Huh-7 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population of Huh-7 cells featuring targeted disruption of the ABHD14B gene. This stable loss-of-function model enables researchers to study ABHD14B’s biological function in hepatocellular carcinoma without the artifacts associated with transient RNA interference. The polyclonal format retains population-level heterogeneity, making it well-suited for pooled functional screening and for experiments where clonal variability is intentionally avoided.
The Huh-7 host cell line was originally isolated from a well-differentiated hepatocellular carcinoma of a 57-year-old Japanese male and displays adherent epithelial morphology. Widely employed in liver cancer research, Huh-7 cells express hepatocyte lineage markers and are permissive to hepatitis C virus replication, thereby providing a physiologically relevant system to dissect oncogenic signaling, metabolic reprogramming, and therapeutic vulnerabilities specific to HCC.
ABHD14B encodes a predicted hydrolase domain-containing protein that has been implicated in protein deacetylation, a reversible post-translational modification critical for the regulation of metabolic enzyme activity. Although its precise substrates remain to be defined, ABHD14B is hypothesized to deacetylate key metabolic enzymes, potentially functioning within multi-protein complexes that coordinate glycolytic, lipogenic, and oxidative pathways. The enzyme is thought to be activated downstream of nutrient-sensing pathways, integrating signals such as AMP/ATP ratios or insulin/glucagon balance to modulate enzyme activity. Consequently, loss of ABHD14B may disrupt deacetylation-dependent metabolic control, leading to aberrant metabolic flux, altered redox balance, and impacts on cell proliferation and survival.
In the Huh-7 hepatocellular carcinoma model, ABHD14B knockout offers a powerful tool to dissect the gene??s role in the metabolic adaptations that drive HCC growth. Because ABHD14B has been linked to tumor suppression and is associated with cancer prognosis, this model allows functional interrogation of whether its loss enhances malignant traits such as increased proliferation, migration, and resistance to apoptosis. By examining ABHD14B-deficient Huh-7 cells, researchers can clarify how deacetylation-dependent metabolic rewiring contributes to liver cancer aggressiveness and identify potential therapeutic nodes.
Typical experimental applications include validation of knockout efficiency by RT-qPCR and Western blot, and phenotypic characterization using MTS/MTS proliferation, Annexin V apoptosis, and Transwell migration/invasion assays. Metabolic flux analyses with Seahorse instruments and whole-transcriptome profiling by RNA-seq can define the metabolic and gene expression consequences of ABHD14B disruption. Moreover, drug sensitivity assays enable screening for compounds that selectively target ABHD14B-null HCC cells, supporting drug target validation and the identification of small-molecule modulators. For further information, please contact Ascent Research.
